Metastatic Prostate Carcinoma — Patent Landscape
2
Approved drugs
110
Active US patents
51/100
Avg vulnerability
$300M
Annual revenue covered
Originators in Metastatic Prostate Carcinoma
Cliff calendar — next 15 years
1
26
11
28
1
29
9
30
4
31
76
32
2
33
2
34
2
37
1
38
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Estrace
ESTRADIOL
|
Pfizer | 101 | 37 | — | 2028-07-10 |
|
Jevtana Kit
cabazitaxel
|
Accord Hlthcare | 9 | 65 | $300M | 2026-06-10 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 12453712 | Jevtana Kit | method of use | 81 | 2030-10-27 |
| 7241907 | Jevtana Kit | other | 80 | 2026-06-10 |
| 10583110 | Jevtana Kit | method of use | 68 | 2030-10-27 |
| 10716777 | Jevtana Kit | method of use | 68 | 2030-10-27 |
| 8927592 | Jevtana Kit | method of use | 68 | 2030-10-27 |
| 12453712 | Jevtana Kit | other | 68 | 2031-04-27 |
| 10716777 | Jevtana Kit | other | 68 | 2031-04-27 |
| 8927592 | Jevtana Kit | other | 68 | 2031-04-27 |
| 10583110 | Jevtana Kit | other | 68 | 2031-04-27 |
| 9730900 | Estrace | method of use | 58 | 2028-07-10 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 11795178 | Estrace | composition of matter | 0 | 2033-09-27 |
| 12325714 | Estrace | composition of matter | 0 | 2033-09-27 |
| 11865179 | Estrace | composition of matter | 0 | 2032-11-21 |
| 11865179 | Estrace | composition of matter | 0 | 2032-11-21 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 8231906 | Estrace | composition of matter | 0 | 2030-07-04 |
| 7300935 | Estrace | composition of matter | 0 | 2029-01-28 |
Related
- Metastatic Prostate Carcinoma — full disease profile
- AI Patent Landscape Report — type "metastatic prostate carcinoma" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner